Durability Still In Question For Acadia's Nuplazid In Alzheimer’s Psychosis
Full Phase II data studying Acadia's Nuplazid (pimavanserin) in patients with Alzheimer’s disease psychosis confirmed the exploratory drug met its primary endpoint, but worries remain over the drug's durability – and hence its commercial promise in dementia-related psychosis.
You may also be interested in...
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.